Compare CRGY & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRGY | PBLS |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.6B |
| IPO Year | 2022 | 2026 |
| Metric | CRGY | PBLS |
|---|---|---|
| Price | $13.27 | $29.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 5 |
| Target Price | $17.47 | ★ $41.75 |
| AVG Volume (30 Days) | ★ 5.1M | 679.6K |
| Earning Date | 11-02-2026 | 11-17-2026 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,579,782,000.00 | N/A |
| Revenue This Year | $39.29 | N/A |
| Revenue Next Year | N/A | $222.58 |
| P/E Ratio | $99.08 | ★ N/A |
| Revenue Growth | ★ 22.14 | N/A |
| 52 Week Low | $7.68 | $25.56 |
| 52 Week High | $15.47 | $42.49 |
| Indicator | CRGY | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 44.05 | 39.57 |
| Support Level | $11.45 | $26.42 |
| Resistance Level | $14.06 | $33.65 |
| Average True Range (ATR) | 0.44 | 3.16 |
| MACD | -0.20 | -0.72 |
| Stochastic Oscillator | 10.07 | 20.05 |
Crescent Energy Co is an energy company committed to delivering value for shareholders through disciplined growth, acquisition ideas, and the consistent return of capital. Its long-life, balanced portfolio combines stable cash flows from low-decline production with deep, high-quality development inventory. The company operates in one reportable segment, which is the exploration and production of crude oil, natural gas, and NGLs.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.